Details of the Drug
General Information of Drug (ID: DMWHK35)
Drug Name |
2,3,4-trihydroxybenzoic acid
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2,3,4-TRIHYDROXYBENZOIC ACID; 610-02-6; 4-Pyrogallolcarboxylic acid; Pyrogallolcarboxylic acid; 2,3,4-Trihydroxybenzoate; Pyrogallol-4-carboxylic acid; UNII-AD1ID2JF5O; Benzoic acid, trihydroxy-; Benzoic acid, 2,3,4-trihydroxy-; 2,3,4-Trihydroxybenzene carboxylic acid; EINECS 210-205-9; NSC 27436; AD1ID2JF5O; BRN 2210807; CHEMBL220779; CHEBI:88714; 2,3,4-Trihydroxybenzoic acid, 97%; AK-94172; W-105210; pyrogallolcarboxylate; trihydroxybenzoic acid; 2,4-Trihydroxybenzoate; AC1L1YC0; 2,4-Trihydroxybenzoic acid; Oprea1_870375
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 170.12 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||